Cancer Family
Bone Marrow Neoplasm
CI-CAN-00000093Explore in graph →
Non-malignant1,034 active trials28 approved drugs633 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000093Explore in graph →
Clinical trials
4,612 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00529880 | Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML | unknown | Phase 2 | 19 | Cooperative Study Group A for HematologyNETWORK | 1 | Sep 27, 2007 | clinicaltrials |
| NCT00517712 | Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia(IAPLSG04) | unknown | Phase 2 / Phase 3 | 400 | Christian Medical College, Vellore, IndiaOTHER | 1 |
| Aug 17, 2007 |
| clinicaltrials |
| NCT00514969 | Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase(CML003) | completed | Phase 2 | — | University of BolognaOTHER | 1 | Aug 10, 2007 | clinicaltrials |
| NCT00510926 | Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase | completed | Phase 2 | 80 | University of BolognaOTHER | 1 | Aug 3, 2007 | clinicaltrials |
| NCT00511121 | Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON) | terminated | Phase 2 | 5 | University of BolognaOTHER | 0 | Aug 3, 2007 | clinicaltrials |
| NCT00511303 | Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia | completed | Phase 2 | 200 | University of BolognaOTHER | 0 | Aug 3, 2007 | clinicaltrials |
| NCT00146913 | AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year | unknown | Phase 2 | 30 | Hospices Civils de LyonOTHER | 1 | Apr 27, 2007 | clinicaltrials |
| NCT00143884 | Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood | terminated | Phase 2 | 30 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 23, 2007 | clinicaltrials |
| NCT00460447 | Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation | unknown | Phase 1 / Phase 2 | 30 | University Hospital Carl Gustav CarusOTHER | 1 | Apr 16, 2007 | clinicaltrials |
| NCT00089596 | Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers | completed | Phase 1 / Phase 2 | 10 | ViaCellINDUSTRY | 1 | Apr 12, 2007 | clinicaltrials |
| NCT00273884 | Amonafide in Combination With Cytarabine in Secondary AML | completed | Phase 2 | 80 | Xanthus Pharmaceuticals, Inc.INDUSTRY | 2 | Feb 19, 2007 | clinicaltrials |
| NCT00329498 | L-Ascorbic Acid Depletion to Treat Acute Myeloid Leukemia and Myelodysplastic Syndromes | suspended | Phase 2 | 25 | Samsung Medical CenterOTHER | 1 | Oct 26, 2006 | clinicaltrials |
| NCT00300664 | A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients. | completed | Phase 2 / Phase 3 | 150 | Royal Marsden NHS Foundation TrustOTHER | 0 | Oct 13, 2006 | clinicaltrials |
| NCT00328237 | Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation | unknown | Phase 2 | 20 | Colorado Blood Cancer InstituteOTHER | 1 | Jun 26, 2006 | clinicaltrials |
| NCT00044733 | Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant | completed | Phase 2 | 38 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | May 18, 2006 | clinicaltrials |
| NCT00153582 | WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML) | unknown | Phase 2 | 25 | Charite University, Berlin, GermanyOTHER | 1 | Feb 22, 2006 | clinicaltrials |
| NCT00219752 | Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years | completed | Phase 2 | 30 | Poitiers University HospitalOTHER | 1 | Dec 22, 2005 | clinicaltrials |
| NCT00219765 | Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients | terminated | Phase 1 / Phase 2 | 30 | Poitiers University HospitalOTHER | 1 | Nov 28, 2005 | clinicaltrials |
| NCT00209833 | Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T | unknown | Phase 2 / Phase 3 | 200 | Hannover Medical SchoolOTHER | 1 | Nov 18, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Sep 27, 2007source: clinicaltrials